Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14292403 | 0.91 | CYP3A4 (0.39) | MAPTPOLBKMT2ANPC1RAB9A | |
| SCHEMBL1207755 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1208386 | 0.89 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1209473 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1208375 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1207180 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTTP53NPC1RAB9A | |
| SCHEMBL1209649 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1208225 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1TP53POLB | |
| SCHEMBL1208498 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1POLBKMT2A | |
| SCHEMBL1208915 | 0.87 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | ALDH1A1 316/4885MAPT 865/4885MEN1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.